key: cord-1010624-2yqdy7sy authors: Lifshitz, Dror; Haas, Jigal; Lebovitz, Oshrit; Raviv, Gil; Orvieto, Raoul; Aizer, Adva title: Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis? date: 2021-10-04 journal: Reprod Biomed Online DOI: 10.1016/j.rbmo.2021.09.021 sha: 3b402df162bb0a3975db3a5ff4c43e0882d4f9dc doc_id: 1010624 cord_uid: 2yqdy7sy Research question Does Pfizer's Covid-19 vaccination detrimentally affect semen analysis parameters? Design We conducted a prospective cohort study in a single large tertiary center in Israel between February and March of 2021. Semen samples of 75 fertile men were analyzed 1-2 months following the second dose of Pfizer's covid-19 vaccine. The semen parameters were compared to the WHO reference ranges. The primary outcome was the percentage of abnormal semen parameters in those vaccinated, i.e. the rates of oligozoospermia, reduced percentage of motile sperm and abnormal sperm morphology. Results The interval from the time of the second vaccine to the date of participation was on average 37 days, with most subjects describing either mild or no side effects after the first or second dose. The mean sperm concentration was 63.2±33.6 10^6 ml with only a single subject (1.3%) with sperm count of 12.5 10^6 ml, considered by the WHO as oligozoospermic. The mean sperm motility percentage was 64.5%±16.7 with only a single subject (1.3%) displaying reduced motility. No significant morphological abnormalities were observed. This constituted a significantly lower percentage of abnormal semen parameters compared with the 5% rates reported in fertile men by the WHO. Conclusions The semen parameters following Covid-19 vaccination were predominantly within normal reference ranges as set by the WHO and do not reflect any causative detrimental effect from COVID-19 vaccination. Our results strengthen the notion that the Pfizer's SARS-CoV-2 vaccine is safe and should be recommended to fertility seeking men. ClinicalTrials.gov number, NCT04778033. The 2019 novel coronavirus disease (Covid-19) is a highly infectious respiratory tract disease, first reported on December 2019 in Wuhan, Hubei Province, China, but has since spread globally. By March 2020, it was declared a pandemic by the WHO and has thus far affected tens of millions worldwide (Wiersinga et al., 2020; Zhu et al., 2020) . The ability of SARS-CoV-2 to cross the blood-testis barrier and affect male fertility is currently under dispute. A potential viral presence in the testes was suggested to be plausible due to the local expression of ACE2 and TMPRSS2 in Leydig cells Ma et al., 2021; Wang and Xu, 2020) . As such a study by Li et al had detected SARS-CoV-2 PCR positive semen in 6 out of 38 patients (15.8%), and found histopathological signs of local elevated immune response and germ cell damage in testicular specimens of 6 deceased SARS-CoV-2 patients . Nonetheless, most studies published so far found no viral traces in the semen of both active disease and recovered patients and a recent review determined the likelihood of SARS-CoV-2 presence in the semen of COVID-19 patients is very small. (Guo et al., 2021; He et al., 2021; Holtmann et al., 2020; Kayaaslan et al., 2020; Pan et al., 2020; Paoli et al., 2020; Song et al., 2020) . Whether by local infection in the testis, due to fever, or through a general systemic inflammatory environment, detrimental effect of Covid-19 infection to male fertility was found (Gacci et al., 2021; He et al., 2021; Li et al., 2020; Orvieto et al., 2021) . In the same previously mentioned study by Li et al, the investigators compared semen analysis parameters of 23 Covid-19 patients with controls and found that 39.1% of those patients (n = 9) had oligozoospermia and 60.9% (n = 14) demonstrated a significant 5 increase in leucocytes in the semen . Similar findings of abnormal semen analysis parameters were also found in a recent study by Gacci et al. Within that cohort, as much as 25% (11 out of 43) of Covid-19 recovered patients were oligo-cryptoazoospermic and 76.7% showed pathological levels of IL-8 in semen (Gacci et al., 2021) . The authors of that study concluded that SARS-CoV-2 infection likely produces male genital tract infection and recovered patients should undergo a follow up for reproductive function. The newly available mRNA SARS-CoV-2 vaccine by Pfizer has been recently evaluated in a large multicenter placebo-controlled RCT. The vaccine is comprised of BNT162b2, a lipid nanoparticle formulated nucleoside-modified RNA (modRNA) encoding the SARS-CoV2 full length spike protein, modified by two Proline mutations. The two 30 µg doses were shown to elicit high SARS-COV2 neutralizing antibody titers alongside high antigen specific CD8+ and Th1 type CD4+ T cell response. It was subsequently shown to be 95% effective in preventing SARS-CoV-2 infection a week following the second dose, with a favorable safety profile in a 2-month median follow up time (Polack et al., 2020) . Prompted by the aforementioned observations of abnormal semen parameters following SARS-CoV2 infection, unfounded claims in the popular media linked a possible correlation between the SARS-CoV-2 vaccine and potential male infertility. In this prospective study, we aimed to investigate the effect of BNT162b2 SARS-CoV-2 vaccination on semen analysis parameters of fertile males. Our initial hypothesis was that the vaccine will not elicit an adverse effect on semen parameters. This assumption was largely based on the relatively favorable safety profile of the vaccine with only 16% of 6 the subjects reported by Pfizer to experience mild to moderate fever after the second dose. (Polack et al., 2020) . In this prospective study 75 fertile men younger than 45 years old were enrolled. Fertile men were considered to be those who previously successfully impregnated their partners without the use of artificial reproductive technology. Recruitment was done using word of mouth among medical staff in the Sheba Medical Center, Tel Hashomer hospital and nearby hospitals, as well as being promoted using social media posts. The subjects volunteered freely and were not paid for participation. We excluded men who were previously diagnosed with SARS-CoV-2 infection or were taking medications known to be detrimental to semen parameters. Those recruited supplied a single sperm sample 1-2 months following the second dose of the vaccination by means of masturbation. At the same time, they filled brief questionnaire with information regarding their medical conditions, pernicious habits, as well as information regarding their reproductive history. The subjects were instructed to abstain from both intercourse and masturbation for at least 2-7 days before they supplied their sample. They were provided with a sterile cup and were asked to refrain from the use of lubricants. All samples were examined in the lab within 30 min to 1 hour from ejaculation by a single highly experienced 7 embryologist (A.A.). The specimens were inspected noting the macroscopic and microscopic properties of the semen. Those parameters included: liquefaction, viscosity, color, volume, PH, sperm concentration (10^6 ml), motility (%), morphology (%) and vitality (%). These parameters were compared to the WHO semen analysis reference range in an attempt to ascertain whether the vaccine affects semen quality (Table 3) For all aforementioned evaluations (concentration, motility, morphology and vitality) two different specimens were examined from each sample and the average was recorded. All samples were discarded immediately after the laboratory evaluations. This study was approved by the ethics committee (Helsinki) of the Sheba Medical Center, Tel Hashomer (#8079-21-SMC). Trial Registration: ClinicalTrials.gov identifier NCT04778033. 8 The most recent reference range for abnormal sperm count was defined by the WHO in 2010 and consisted the lower 5 th percentile of sperm parameters in their cohort of fertile men (Cooper et al., 2010) . Those parameters included semen volume, sperm concentration, percentage of motile sperm, percentage of progressive motile sperm, sperm morphology and vitality percentages. Based on this reference range, 5% of fertile men in the general population will produce abnormal results. In order to investigate the effect of SARS-CoV-2 vaccination, a sample size of 75 participants was estimated to be sufficient to reveal a difference in abnormal sperm concentration (oligospermia) from a baseline of 5% to a proposed 15% after vaccination, with a type 1 error (alpha) of 5% and a type 2 error (beta) of 20%. This would represent a 10% increase in aberrant semen parameters, a significantly milder affect compared to that described following infection with reported oligozoospermia rates of 25-40%. (Gacci et al., 2021; Li et al., 2020) Descriptive statistics were computed as mean, median and standard deviation (SD) for continuous variables and as frequencies for categorical variables. All statistical analyses were performed using IBM SPSS Statistics version 27. The study population consists of 75 fertile men with a mean age 38.6 ±4.3 who volunteered to participate in our study. Table 1 describes the socio-demographic characteristics of our participants. The majority of our subjects (90.7%) are healthy with 9 no chronic medical conditions. Since medical staff were among the first to receive the vaccine, they were targeted earlier and comprise 40% of recruited men. Pernicious habits were rare, only 12% reported smoking, 20% on social alcohol consumption and 4% reported marijuana use. The reproductive history of our subjects is also described in table 1. The median number of children in our study group was 2, and 80% of our subjects successfully impregnated their partners within the last 5 years. The interval from the time of the second vaccine to the date of participation was on average 37days. The majority of our subjects experienced (Table 2 ) either no side effects (32%) after vaccination, or only mild side effects such as fatigue (34.7%) and pain at the injection site (13.3%). Systemic effects were relatively rare; only 9.3% experienced fever and 8% experienced chills. The sperm analysis parameters of our subjects are described in table 3 alongside a comparison to the WHO most recent reference range. The mean sperm concentration in our cohort was 63.2 10^6 ml with only a single subject (1.3%) with sperm count of 12.5 10^6 ml, considered by the WHO as oligozoospermic. The mean total motile percentage was 64.5% with only a single subject (1.3%) displaying reduced motility and no progressive motility at all. No significant morphological abnormalities were observed. This study was designed to identify potential detrimental effect of the SARS-CoV-2 vaccine by Pfizer on male fertility. Although previous reports demonstrated increased risk of sperm count abnormalities amongst active and recovered SARS-CoV-2 infected patients (Gacci et al., 2021; He et al., 2021; Li et al., 2020) , in the present study we could not demonstrate any evidence of adverse effects on semen parameters following COVID-19 vaccination. Semen analysis is routinely used in the workup of the infertile couple. Threshold values to classify men as fertile, sub fertile or infertile have varied significantly in different studies. In 2001 a study by Guzick et al, semen specimens of 765 infertile and 696 fertile couples were evaluated. The mean ±SD sperm concentration in the fertile group was 67±50×10^6 per ml, the mean percentage of motile sperm was 54±13 percent, and the mean percentage of normal sperm morphology was 14±5 percent 18 . In the past 40 years, the WHO has revised its lower reference values for normal semen analysis parameters five times. The most recent criteria published in 2010 is based on the semen specimens of 4500 fertile men with a time to pregnancy of less than 12 months. The lower boundary was determined by the 5th percentile of that group and is displayed alongside our results in table 3 (Cooper et al., 2010) . There is scarce evidence regarding the effect of different types of vaccinations on semen parameters or male fertility. Recently, our group reported on 36 couples undergoing consecutive ovarian stimulation (OS) cycles for IVF before and after receiving mRNA SARS-CoV-2 vaccine (Orvieto et al., 2021) . No differences were observed between the IVF treatment variables, number of oocytes, fertilization rate, or semen analyses. Moreover, a recently published research letter by Gonzales et al found no significant decreases in any sperm parameter following 2 doses of Covid-19 MRNA vaccine in 45 men (Gonzalez et al., 2021) . We found no other study which investigated the association between SARS-CoV-2 vaccinations and male fertility. Though technologically different, a study by Catherino et al found no effect on semen parameters, embryo quality or pregnancy outcome in anthrax vaccinated US military service members (Catherino et al., 2005) . Similarly, Smallpox vaccination was not found to negatively affect male fertility in a large epidemiologic study (Jacobson et al., 2008) . In a study conducted on rodents no effect of HPV Gardasil vaccine on sperm parameters and reproductive performance was found (Wise et al., 2010) . With the exception of two specimens (2 out 75, 2.6%), one oligozoospermic and one with reduced motility, none of the vaccinated men in our study produced abnormal results. This constitutes a significantly lower percentage of oligozoospermia than that reported in fertile male by the WHO (5%) (Cooper et al., 2010) , by Guzick et al (~5%), or in recovered and active SARS-CoV-2 patients (25-40%) (Gacci et al., 2021; Li et al., 2020) . Therefore, our study figures are expected in normal fertile population and do not reflect any causative detrimental effect of COVID-19 vaccination. As such, our results combined with those previously reported by Gonzalez et al, suggest that vaccination is safe with no significant detrimental effect on sperm parameters. There are several limitations to our study. Our subjects consisted of a relatively homogenic group of fertile men from high socio-economic status. Those participated were only tested once after they were vaccinated and a subtle potential decrease in sperm parameters could be possible if a semen sample was obtained before vaccination for comparison. This drawback was expected as the vast majority fertile men in Israel were swiftly vaccinated within weeks of vaccine availability, which did not allow consecutive testing. The rapid vaccine coverage also explains why we chose to compare the sperm parameters to the WHO reference as opposed to a control group; which would have been 12 very difficult to recruit under such time constraints. As our participants were only followed 1-2 months after the second dose of the vaccine, thus long-term results are not yet reported. Finally, only a small percentage of our subjects (9.3%) experienced systemic side effects such as fever by the vaccine compared with those tested by Pfizer (16%) (Polack et al., 2020) . This might be explained by the relatively younger age of our cohort. Nevertheless, as we report a relatively large cohort of 75 participants, with only a handful borderline sperm specimen, and considering spermatogenesis spans on average 70-90 days within our time frame, it likely accurately reflects a clinically non substantial affect. In a joint statement by the SMRU and SSMR they state that the SARS-CoV-2 vaccines should be offered to men desiring fertility ("Joint Statement Regarding COVID-19 Vaccine in Men Desiring Fertility from the Society for Male Reproduction and Urology (SMRU) and the Society for the Study of Male Reproduction (SSMR) | ASRM," n.d.). Despite this statement, unfounded claims in popular media linked a possible correlation between the SARS-CoV-2 vaccine and potential male infertility. Such false claims by anti-vaccine activists aim to incite fear and deter public opinion from vaccination, consequently jeopardizing the vaccination plan and the end to the pandemic. Our results refute such claims and strengthen the notion that the Pfizer's SARS-CoV-2 vaccine is safe and should be recommended to fertility seeking men. Anthrax vaccine does not affect semen parameters, embryo quality, or pregnancy outcome in couples with a vaccinated male military service member Structure analysis of the receptor binding of 2019-nCoV World Health Organization reference values for human semen characteristics Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19 Sperm Parameters Before and After COVID-19 mRNA Vaccination Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort Effect of COVID-19 on Male Reproductive System -A Systematic Review Assessment of SARS-CoV-2 in human semen—a cohort study Smallpox vaccination is not associated with infertility in a healthy young adult population 19-vaccine-in-men-desiring-fertility-from-the-societyfor-male-reproduction-and-urology-smru-and-the-society-for-the-study-of-malereproduction-ssmr Investigation of SARS-CoV-2 in Semen of Patients in the Acute Stage of COVID-19 Infection Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients Does COVID-19 infection influence patients' performance during IVF-ET cycle?: an observational study No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019 Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Absence of 2019 novel coronavirus in semen and testes of COVID-19 patients † 2020. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Lack of effects on male fertility from a quadrivalent HPV vaccine in Sprague-Dawley rats A Novel Coronavirus from Patients with Pneumonia in China 10^6 ml) 63.2±33.6,60 Motility (%) 64.5%±16.7,64 Progressive motility (%) 53.8%±16.6,53 Dr Dror Lifshitz obtained his MD degree in 2018 as a graduate of the Sackler Faculty of Medicine in Tel-Aviv. He is currently in his third year of residency in the Department of Obstetrics and Gynaecology at the Sheba Medical Center The authors would like to thank Ms. Moran Madari for her contributions to data collection and secretarial assistance.